Thermo Fisher’s test to detect pregnancy-related complication gets FDA nod

FDA

Thermo Fisher’s test to detect pregnancy-related complication gets FDA nod

May 19 (Reuters) – The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific Inc’s (TMO.N) test, the first of its kind in the country, to detect women with risk of severe preeclampsia, the company said on Friday.

Preeclampsia is a leading cause of mortality in pregnant women globally, where they could experience high blood pressure after 20 weeks of pregnancy and during the postpartum period.

The condition happens in about 1 in 25 pregnancies in the United States, according to the U.S. Centers for Disease Control and Prevention.

The FDA clearance is based on a study that examined data from over 700 pregnant women in 18 U.S. hospitals.

The regulatory nod for the biomarker test will have a significant impact on prognosis and treatment for thousands of women at risk for preeclampsia every year in the U.S, said Alan Sachs, chief medical officer at Thermo Fisher Scientific.

Reporting by Khushi Mandowara in Bengaluru; Editing by Shailesh Kuber

Our Standards: The Thomson Reuters Trust Principles.

Source: Reuters

/by
You might also like
US government restarts delivery of free COVID tests
AstraZenecaSarepta slides as surprise FDA panel meet adds uncertainty for gene therapy
FDAAkebia’s CKD anemia drug ends tough regulatory path with FDA approval
FDAUS FDA approves CorMedix’s drug for bloodstream infections
FDAUS FDA identifies recall of Philips medical imaging devices as most serious
job cuts, layoffsMirati CEO steps down after going toe-to-toe with Amgen in KRAS
LeqembiFDA panel to debate US approval for Alzheimer’s drug from Eisai and Biogen
AstraZenecaAstraZeneca’s Tagrisso-chemo combo given priority review in US